Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A War Within the War.
Torniai M, Gucciardino C, Esperide B, Del Prete M, Lanese A, Bisonni R. Torniai M, et al. Among authors: bisonni r. J Clin Oncol. 2022 Dec 1;40(34):4025-4026. doi: 10.1200/JCO.22.00745. Epub 2022 Aug 5. J Clin Oncol. 2022. PMID: 35930756 No abstract available.
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab.
Ruzzo A, Graziano F, Bagaloni I, Di Bartolomeo M, Prisciandaro M, Aprile G, Ongaro E, Vincenzi B, Perrone G, Santini D, Fornaro L, Vivaldi C, Tomasello G, Loupakis F, Lonardi S, Fassan M, Valmasoni M, Sarti D, Lorenzini P, Catalano V, Bisonni R, Del Prete M, Collina G, Magnani M. Ruzzo A, et al. Among authors: bisonni r. Gastric Cancer. 2020 Nov;23(6):1064-1074. doi: 10.1007/s10120-020-01078-0. Epub 2020 May 5. Gastric Cancer. 2020. PMID: 32372141 Free PMC article.
TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy.
Graziano F, Fischer NW, Bagaloni I, Di Bartolomeo M, Lonardi S, Vincenzi B, Perrone G, Fornaro L, Ongaro E, Aprile G, Bisonni R, Prisciandaro M, Malkin D, Gariépy J, Fassan M, Loupakis F, Sarti D, Del Prete M, Catalano V, Alessandroni P, Magnani M, Ruzzo A. Graziano F, et al. Among authors: bisonni r. Cancers (Basel). 2020 Jul 24;12(8):2049. doi: 10.3390/cancers12082049. Cancers (Basel). 2020. PMID: 32722340 Free PMC article.
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer.
Giampieri R, Cantini L, Del Prete M, Bittoni A, Giglio E, Mandolesi A, Maccaroni E, Lanese A, Meletani T, Baleani MG, Bisonni R, Scarpelli M, Berardi R. Giampieri R, et al. Among authors: bisonni r. Oncol Lett. 2021 Apr;21(4):267. doi: 10.3892/ol.2021.12528. Epub 2021 Feb 9. Oncol Lett. 2021. PMID: 33717264 Free PMC article.
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Buti S, Bersanelli M, Perrone F, Bracarda S, Di Maio M, Giusti R, Nigro O, Cortinovis DL, Aerts JGJV, Guaitoli G, Barbieri F, Ferrara MG, Bria E, Grossi F, Bareggi C, Berardi R, Torniai M, Cantini L, Sforza V, Genova C, Chiari R, Rocco D, Della Gravara L, Gori S, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Citarella F, Russano M, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Follador A, Bisonni R, Tuzi A, Minuti G, Landi L, Ricciardi S, Migliorino MR, Tabbò F, Olmetto E, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Addeo A, Friedlaender A, Cannita K, Porzio G, Ficorella C, Carmisciano L, Pinato DJ, Mazzaschi G, Tiseo M, Cortellini A. Buti S, et al. Among authors: bisonni r. Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3. Eur J Cancer. 2021. PMID: 33934059 Free article.
Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients.
Bittoni A, Giampieri R, Pecci F, Pinterpe G, Mandolesi A, Del Prete M, Zizzi A, Crocetti S, Liguori C, Mentrasti G, Cantini L, Pellei C, Bisonni R, Scarpelli M, Berardi R. Bittoni A, et al. Among authors: bisonni r. Curr Oncol. 2021 Sep 9;28(5):3525-3536. doi: 10.3390/curroncol28050303. Curr Oncol. 2021. PMID: 34590611 Free PMC article.
Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy.
Giampieri R, Baleani MG, Bittoni A, Rastelli F, Catalano V, Del Prete M, Chiorrini S, Pinterpe G, Graziano F, Giorgi FC, Bisonni R, Silva R, Alessandroni P, Mencarini L, Berardi R. Giampieri R, et al. Among authors: bisonni r. Cancers (Basel). 2023 Jun 25;15(13):3342. doi: 10.3390/cancers15133342. Cancers (Basel). 2023. PMID: 37444451 Free PMC article.
Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic.
Parisi A, Giampieri R, Villani S, Magnarini A, Gelsomino F, Traisci D, Barbin F, Salvatore L, Zichi C, Di Pietro FR, Zoratto F, Lanese A, Petrillo A, Zurlo IV, Spallanzani A, D'Ostilio N, Ghidini M, Bensi M, Schietroma F, Rognone C, Panepinto O, Paparo J, Gamba T, Bisonni R, Di Lorenzo S, Daniele B, Mentrasti G, Berardi R. Parisi A, et al. Among authors: bisonni r. Oncologist. 2024 Nov 26:oyae310. doi: 10.1093/oncolo/oyae310. Online ahead of print. Oncologist. 2024. PMID: 39591103 Free article.
Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer.
Catalano V, Loupakis F, Graziano F, Bisonni R, Torresi U, Vincenzi B, Mari D, Giordani P, Alessandroni P, Salvatore L, Fornaro L, Santini D, Baldelli AM, Rossi D, Giustini L, Silva RR, Falcone A, D'Emidio S, Rocchi M, Luzi Fedeli S. Catalano V, et al. Among authors: bisonni r. Ann Oncol. 2012 Jan;23(1):135-141. doi: 10.1093/annonc/mdr062. Epub 2011 Apr 29. Ann Oncol. 2012. PMID: 21531784 Free article.
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Kopp RM, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Massari F, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Sunela K, Bassanelli M, Ortega C, Grillone F, Landmesser J, Milella M, Messina C, Küronya Z, Mosca A, Bhuva D, Santini D, Vau N, Morelli F, Incorvaia L, Rebuzzi SE, Roviello G, Soares A, Bisonni R, Bimbatti D, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Battelli N, Bracarda S, Porta C. Santoni M, et al. Among authors: bisonni r. Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21. Eur Urol Oncol. 2024. PMID: 37481365
43 results